8-K: Trustfeed Corp. Completes Acquisition of Polomar Specialty Pharmacy, Shifts Focus to Telehealth and Compounding Pharmacy

Trustfeed Corp. has finalized its acquisition of Polomar Specialty Pharmacy, marking a significant shift in its business operations towards telehealth and prescription compounding.

Summary

• Trustfeed Corp. completed the acquisition of Polomar Specialty Pharmacy on September 30, 2024, making Polomar a wholly-owned subsidiary.
• The acquisition involved exchanging all outstanding membership interests of Polomar for approximately 207,414,147 shares of Trustfeed's common stock.
• CWR 1, LLC, Trustfeed's majority owner, canceled 50,000,000 of its shares as part of the acquisition conditions.
• Following the acquisition, the former Polomar members now own approximately 75% of Trustfeed's outstanding common stock.
• Trustfeed has ceased its previous business operations and will now focus on Polomar's compounding pharmacy business.
• Polomar is a licensed retail and sterile compounding pharmacy in Florida, authorized to dispense medications in 28 states, with plans to expand to a majority of U.S. states by the end of 2025.
• The company also acquired SlimRx, an online platform for weight loss medication prescriptions, and plans to launch PoloMeds for diabetes and erectile dysfunction medications.
• Trustfeed intends to provide prescription fulfillment services for third-party telehealth platforms.
• The company has licensed intellectual property for aerosol-based medication delivery systems.
• Trustfeed faces competition from established players like Hims/Hers and Ro, as well as direct competition from Lilly Direct and Levity Healthcare/ZipHealth.

Sentiment

Score: 4

Explanation: The document presents a mixed picture. While the acquisition and new business direction are positive, the company's financial situation, competition, and risks associated with a development stage company temper the overall sentiment. The company's history of losses and need for additional capital are significant concerns.

Positives

• The acquisition provides Trustfeed with a licensed compounding pharmacy and a telehealth platform.
• Polomar's licenses allow for dispensing medications in 28 states, with plans for further expansion.
• The company has acquired SlimRx, a weight loss focused online platform, and plans to launch PoloMeds, expanding its product offerings.
• The company has licensed a novel aerosol-based medication delivery system, which may provide a competitive advantage.
• Trustfeed intends to provide prescription fulfillment services for third-party telehealth platforms, creating a potential revenue stream.
• The company has a 2024 Equity and Incentive Compensation Plan to attract and retain key personnel.

Negatives

• Trustfeed has a limited operating history and is in a development stage.
• The company has a history of net losses and expects to continue incurring losses.
• Trustfeed is dependent on related party short-term debt and other current liabilities.
• The company faces strong competition in the online prescription fulfillment market.
• The company may face challenges in protecting its intellectual property.
• The company's common stock is subject to penny stock rules, which may reduce its value.
• The company has identified internal control deficiencies, which management and our independent auditors believe constitute material weaknesses.
• The company may not be able to raise additional capital to finance its operations.

Risks

• The company is a development stage company with a limited operating history, making it difficult to evaluate its business.
• The company may not be successful in carrying out its business objectives or achieving profitability.
• The company may not be able to obtain additional financing, which could impact its operations.
• The company is subject to significant related party short-term debt and other current liabilities, which it may be unable to repay.
• The company faces strong competition from established players in the online prescription fulfillment market.
• The company is dependent on licensed patent and other proprietary rights, and may face litigation related to intellectual property.
• The company's common stock has a limited trading market and is subject to penny stock rules.
• The company may not be able to manage rapid growth effectively.
• The company has identified internal control deficiencies, which management and our independent auditors believe constitute material weaknesses.
• The company may not meet its development and commercialization milestones.

Future Outlook

The company expects to expand its prescription medication services to a majority of U.S. states by the end of 2025 and anticipates applying for a drug export permit in early 2025. The company also plans to launch PoloMeds during the fourth quarter of 2024 and expects steady growth in its wholesale business over the next twelve to eighteen months.

Management Comments

• New management anticipated entering into a future transaction involving the Company, which could result in the acquisition of one or more businesses, companies or asset classes.
• The Companys new management evaluated the Companys Pre-Existing Business as part of these possible future transactions, and in the meantime, suspended our operations relating to the Pre-Existing Business.
• The Company believes these medical devices, which utilize an aerosol-based system, may significantly increase drug bioavailability and thereby decrease the time required for drugs to become effective.
• We believe our pre-filled injection pen system will provide an easier, better, and more comfortable user experience thereby providing us a potential marketing advantage.
• We believe that our integrated platform delivering telemedicine to patients and directly fulfilling prescription may provide an advantage and is likely to provide better margins on the products we sell.

Industry Context

This announcement reflects a growing trend in the healthcare industry towards telehealth and online pharmacies, with companies like Hims/Hers and Ro leading the way. Trustfeed's acquisition of Polomar and its focus on compounding pharmacy and telehealth platforms positions it to compete in this evolving market. The company's strategy of integrating telemedicine with prescription fulfillment is a common approach in the industry, aiming to provide a seamless experience for patients.

Comparison to Industry Standards

• Hims/Hers and Ro are significant competitors in the online prescription fulfillment market, particularly for GLP-1 agonist weight loss drugs and erectile dysfunction formulations.
• Lilly Direct, a direct-to-consumer platform from Eli Lilly, competes directly by offering discounted prices for Zepbound, a tirzepatide medication.
• Levity Healthcare/ZipHealth provides similar compounding services, utilizing their own provider group, offering weight loss drugs and consultation.
• Hims/Hers and Ro currently sub-contract their prescription fulfillment to other licensed compounding pharmacies, while Trustfeed will directly fulfill prescriptions through Polomar.
• Unlike competitors who deliver injectable drugs in vials with syringes, Trustfeed plans to use pre-filled injection pens, which they believe will be more attractive to consumers.
• Lilly Direct offers Zepbound directly to the customer at between $399 and $549 per month, a significant discount over local pharmacies, while Trustfeed expects to be competitive on pricing.
• ZipHealth is presently licensed in 25 states and has publicly announced that they expect to continue expanding, while Trustfeed is currently licensed in 28 states with plans to expand to a majority of U.S. states by the end of 2025.

Management Changes

Corporate Governance

Related Party Transactions

• Fastbase, Inc. sold 90,437,591 shares of common stock and 500,000 shares of preferred stock to CWR for $350,000.
• Affiliates of CWR and GLDLP have funded the company's expenses, including expenses incurred by it as a result of being a public company, totaling $831,425 since the Transaction through September 30, 2024.
• CWR transferred back to the Company and canceled 50,000,000 shares of common stock as part of the acquisition conditions.
• Affiliates of CWR beneficially owned approximately 45% of Polomar, and post-Closing acquired an aggregate of 94,580,845 shares of our Common Stock as merger consideration therefor.

Stakeholder Impact

• Shareholders will experience a significant change in the company's business direction and ownership structure.
• Employees will be impacted by the shift in business focus and potential changes in roles and responsibilities.
• Customers will have access to new telehealth and prescription fulfillment services.
• Suppliers will be impacted by the company's new focus on compounding pharmacy and related products.
• Creditors will be impacted by the company's debt obligations and need for additional financing.

Next Steps

• The company intends to implement the Name Change, Authorized Stock Increase, and Reverse Stock Split as soon as practicable.
• The company plans to launch PoloMeds during the fourth quarter of 2024.
• The company expects to expand its prescription medication services to a majority of U.S. states by the end of 2025.
• The company anticipates applying for a drug export permit in early 2025.
• The company intends to file Polomars audited financial statements for the period from April 26, 2023 (inception) through December 31, 2023, and its unaudited financial statements for and as of the three and six months ended June 30, 2024 as an amendment to this Form 8-K within seventy-one days of the date of the filing of this Current Report on Form 8-K with the Securities and Exchange Commission.
• The company intends to file the financial information required by paragraph (b) of Item 9.01 as an amendment to this Form 8-K within seventy-one days of the date of this Current Report on Form 8-K as filed with the Securities and Exchange Commission.

Key Dates

Keywords

compounding pharmacy, telehealth, prescription fulfillment, pharmaceuticals, weight loss, diabetes, erectile dysfunction, intellectual property, acquisition, reverse merger